BiotechTube

YM443 + Placebo + Moxifloxacin

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Functional Dyspepsia

Conditions

Functional Dyspepsia

Trial Timeline

Feb 1, 2009 → Apr 1, 2009

NCT ID
NCT00850746

About YM443 + Placebo + Moxifloxacin

YM443 + Placebo + Moxifloxacin is a phase 1 stage product being developed by Astellas Pharma for Functional Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT00850746. Target conditions include Functional Dyspepsia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00850746Phase 1Completed

Competing Products

20 competing products in Functional Dyspepsia

See all competitors
ProductCompanyStageHype Score
YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + PlaceboYuhanPhase 2
52
YH12852 IR 0.05mg + YH12852 IR 0.1mg + YH12852 IR 0.3mg + YH12852 IR 0.5mg + YH12852 IR 1mg + YH12852 IR 2mg + YH12852 IR 3mg + YH12852 DR1 0.5mg + YH12852 DR1 1mg + YH12852 DR1 2mg + YH12852 DR1 4mg + YH12852 DR2 8mg + Prucalopride 2mg + PlaceboYuhanPhase 1/2
41
Rabeprazole + Rabeprazole + Rabeprazole + PlaceboEisaiPhase 2
52
Imonogas + EspumisanJohnson & JohnsonPhase 3
77
Linaclotide + PlaceboAbbViePhase 3
77
Linaclotide + Placebo for LinaclotideAbbViePhase 3
77
Linaclotide + PlaceboAbbViePhase 2
52
Quetiapine (50 mg/day-100mg/day)AstraZenecaPre-clinical
23
NKTR-118AstraZenecaPhase 1
33
PDR001NovartisPhase 2
52
Human GLP-1 (7-36) amide + Isotone NaClNovo NordiskPre-clinical
22
psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo)PfizerPre-clinical
22
Gabapentin + PlaceboPfizerPhase 3
76
Z-338Zeria PharmaceuticalPhase 2
51
Z-338 + PlaceboZeria PharmaceuticalPhase 3
76
Acotiamide hydrochloride hydrate + PlaceboZeria PharmaceuticalPhase 3
76
Z-338Zeria PharmaceuticalPhase 2
51
MibavademabRegeneron PharmaceuticalsPhase 2
51
STW5 (Iberogast®, BAY98-7411) + PlaceboBayerPhase 2
49
Iberogast (STW5-II, BAY98-7410)BayerPre-clinical
20

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85